click to watch our newest corporate video
We are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. Our mission is to harness transformative science and global partnerships to bring innovative vaccines to populations worldwide.
Our COVID-19 vaccine, SCB-2019 (CpG 1018/Alum), has been authorized for emergency use in China. We are also developing candidates leveraging the Trimer-Tag™ technology and designed to be broadly protective against currently circulating and potential future strains of the SARS-CoV-2 virus.
The Trimer-Tag™ technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets.
We have built our product pipeline by employing the Trimer-Tag™ technology platform.
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
